Skip to Content

Glucagonlike Peptide 1-Based Therapies Associated With Acute Pancreatitis in Study

In a study by Sonal Singh, M.D., M.P.H., of The Johns Hopkins University School of Medicine, Baltimore, and colleagues, treatment with the glucagonlike peptide-1 (GLP-1)-based therapies sitagliptin and exenatide were associated with increased odds of hospitalization for acute pancreatitis in adults with type 2 diabetes mellitus. (Online First)


The population-based case-control study used a large administrative database of adults with type 2 diabetes. Researchers identified 1,269 hospitalized cases with acute pancreatitis and 1,269 matched controls. The average age of the patients was 52 years and almost 58 percent of them were men, according to the study.


“In summary, acute pancreatitis has significant morbidity and mortality. In this administrative database study of U.S. adults with type 2 diabetes mellitus, treatment with the GLP-1-based therapies sitagliptin and exenatide was associated with an increased risk of hospitalization for acute pancreatitis,” the study concludes.

(JAMA Intern Med. Published online February 25, 2013. doi:10.1001/jamainternmed.2013.2720. Available pre-embargo to the media at


Editor’s Note: This study was supported by the Johns Hopkins Clinical Research Scholars Program, by a grant from the National Center for Research Resources and by the NIH Roadmap for Medical Research. Please see article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.


# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email

Posted: February 2013